Recently, Jänne and colleagues showed that the combination of the MEK inhibitor, selumetinib, and docetaxel have a synergistic effect in advanced KRAS-mutated NSCLC [20, 21]. The gene discussed is MAP2K7; the disease is non-small cell lung carcinoma.